Ruxolitinib Versus Best Available Therapy in Patients With Glucocorticoid-Refractory Chronic Graft-Vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [41] Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
    von Bubnoff, Nikolas
    Ihorst, Gabriele
    Grishina, Olga
    Roethling, Nadine
    Bertz, Hartmut
    Duyster, Justus
    Finke, Juergen
    Zeiser, Robert
    BMC CANCER, 2018, 18
  • [42] Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
    Nikolas von Bubnoff
    Gabriele Ihorst
    Olga Grishina
    Nadine Röthling
    Hartmut Bertz
    Justus Duyster
    Jürgen Finke
    Robert Zeiser
    BMC Cancer, 18
  • [43] JAK/Rock Inhibitor TQ05105 for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease: Preliminary Analysis Results of a Phase 1b/2 Study
    Zhao, Yanmin
    Tu, Lifan
    Ye, Yishan
    Luo, Yi
    Shi, Jimin
    Yu, Jian
    Yu, Yi
    Meng, Fankai
    Wang, Tao
    Huang, He
    BLOOD, 2022, 140 : 10505 - 10506
  • [44] RUXOLITINIB PROVES SUPERIOR TO BEST AVAILABLE THERAPY IN A PROSPECTIVE, RANDOMIZED, PHASE 3 STUDY (RESPONSE) IN PATIENTS WITH POLYCYTHEMIA VERA RESISTANT TO OR INTOLERANT OF HYDROXYUREA
    Vannucchi, A. M.
    Kiladjian, J. J.
    Griesshammer, M.
    Masszi, T.
    Durrant, S.
    Passamonti, F.
    Harrison, C. N.
    Pane, F.
    Zachee, P.
    Mesa, R.
    He, S.
    Jones, M. M.
    Garrett, W.
    Li, J.
    Francillard, N.
    Habr, D.
    Verstovsek, S.
    HAEMATOLOGICA, 2014, 99 : 790 - 790
  • [45] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (vol 30, pg 1701, 2016)
    Harrison, C. N.
    Vannucchi, A. M.
    Kiladjian, J-J
    Al-Ali, H. K.
    Gisslinger, H.
    Knoops, L.
    Cervantes, F.
    Jones, M. M.
    Sun, K.
    McQuitty, M.
    Stalbovskaya, V.
    Gopalakrishna, P.
    Barbui, T.
    LEUKEMIA, 2017, 31 (03) : 775 - 775
  • [46] Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients
    Dang, Si-Hua
    Liu, Qin
    Xie, Rong
    Shen, Na
    Zhou, Shu
    Shi, Wei
    Liu, Wen
    Zou, Ping
    You, Yong
    Zhong, Zhao-Dong
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (06) : 1065 - 1073
  • [47] Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute Graft-vs-host disease: 6-month follow-up data from the phase 2 REACH1 trial
    Jagasia, Madan
    Ali, Haris
    Schroeder, Mark A.
    Shah, Nirav N.
    Chen, Yi-Bin
    Dawkins, Fitzroy
    Arbushites, Michael
    Tian, Chuan
    Perales, Miguel-Angel
    BONE MARROW TRANSPLANTATION, 2019, 54 : 79 - 80
  • [48] A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease
    Kebriaei, Partow
    Hayes, Jack
    Daly, Andrew
    Uberti, Joseph
    Marks, David, I
    Soiffer, Robert
    Waller, Edmund K.
    Burke, Elizabeth
    Skerrett, Donna
    Shpall, Elizabeth
    Martin, Paul J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (05) : 835 - 844
  • [49] Trial Design of a Phase 3, Randomized, Open-Label, Multicenter Study (REACH-2) to evaluate Ruxolitinib over BAT in Patients with Corticosteroid-Refractory Acute Graft-Versus-Host Disease Post Allo-HSCT
    Socie, Gerard
    Niederwieser, Dietger
    Szer, Jeff
    Mohty, Mohamad
    Zeiser, Robert
    Gadbaw, Brian
    Molloy, Betty
    O'Sullivan-Djentuh, Leslie
    von Bubnoff, Nikolas
    BONE MARROW TRANSPLANTATION, 2018, 53 : 462 - 463
  • [50] Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study
    Locatelli, Franco
    Antmen, Bulent
    Kang, Hyoung Jin
    Koh, Katsuyoshi
    Takahashi, Yoshiyuki
    Kupesiz, Alphan
    Matos, Maria Gabriela A. Dias
    Chopra, Yogi
    Bhat, Sunil
    Im, Ho Joon
    Guengoer, Tayfun
    Lu, Meng-Yao
    Stefanelli, Tommaso
    Rosko, Christine
    St Pierre, Annie
    Burock, Karin
    Smith, Yvonne
    Sinclair, Karen
    Diaz-de-Heredia, Cristina
    LANCET HAEMATOLOGY, 2024, 11 (08): : e580 - e592
12345